Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity

Nature Medicine

Volumn 23, Issue 2, 2017, Pages 242-249

  Ghosh, Arnab ^a   Smith, Melody ^a   James, Scott E ^a   Davila, Marco L ^a,d   Velardi, Enrico ^a   Argyropoulos, Kimon V ^a   Gunset, Gertrude ^a   Perna, Fabiana ^a   Kreines, Fabiana M ^a   Levy, Emily R ^a   Lieberman, Sophie ^a   Jay, Hillary V ^a   Tuckett, Andrea Z ^a   Zakrzewski, Johannes L ^a   Tan, Lisa ^a   Young, Lauren F ^a   Takvorian, Kate ^a   Dudakov, Jarrod A ^a,e   Jenq, Robert R ^a   Hanash, Alan M ^a   Motta, Ana Carolina F ^b,f   Murphy, George F ^b   Liu, Chen ^c   Schietinger, Andrea ^a   Sadelain, Michel ^a   Van Den Brink, Marcel R M ^a   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e USA   (United States)

^f UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CD137 ANTIGEN; CD18 ANTIGEN; CD19 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; T LYMPHOCYTE RECEPTOR; CD137 LIGAND; CD28 ANTIGEN; CYTOKINE; LYMPHOCYTE ANTIGEN RECEPTOR;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOREACTIVE T CELL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STIMULATION; CELL THERAPY; CONTROLLED STUDY; EFFECTOR CELL; EXHAUSTION; FEMALE; GENE LOSS; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LYMPHOMA EFFECT; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; ORGAN DONOR; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TUMOR XENOGRAFT; ADOPTIVE TRANSFER; ALLOTRANSPLANTATION; ANIMAL; B LYMPHOCYTE; CHIMERA; DISEASE MODEL; FLOW CYTOMETRY; GRAFT VERSUS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; LYMPHOMA; METABOLISM;

4-1BB LIGAND; ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, CD19; ANTIGENS, CD28; B-LYMPHOCYTES; CHIMERA; CYTOKINES; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; GRAFT VS HOST DISEASE; GRAFT VS HOST REACTION; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LYMPHOMA; MICE; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 85008600121     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.4258     Document Type: Article

References (43)

1. Ho, W.Y., Blattman, J.N., Dossett, M.L., Yee, C. & Greenberg, P.D. Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell 3, 431-437 (2003).
2. Sadelain, M., Rivière, I. & Brentjens, R. Targeting tumours with genetically enhanced T lymphocytes. Nat. Rev. Cancer 3, 35-45 (2003).
3. Gill, S. & June, C.H. Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. Immunol. Rev. 263, 68-89 (2015).
4. Sadelain, M., Brentjens, R. & Rivière, I. The basic principles of chimeric antigen receptor design. Cancer Discov. 3, 388-398 (2013).
5. James, S.E. et al. Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice. Blood 114, 5454-5463 (2009).
6. Brentjens, R.J. et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat. Med. 9, 279-286 (2003).
7. Sadelain, M. CAR therapy: the CD19 paradigm. J. Clin. Invest. 125, 3392-3400 (2015).
8. Kochenderfer, J.N. et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J. Clin. Oncol. 33, 540-549 (2015).
9. Kalos, M. et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3, 95ra73 (2011).
10. Brentjens, R.J. et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118, 4817-4828 (2011).
11. Brentjens, R.J. et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5, 177ra38 (2013).
12. Grupp, S.A. et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509-1518 (2013).
13. Davila, M.L. et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6, 224ra25 (2014).
14. Lee, D.W. et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385, 517-528 (2015).
15. Maude, S.L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507-1517 (2014).
16. Brudno, J.N. et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J. Clin. Oncol. 34, 1112-1121 (2016).
17. Kochenderfer, J.N. et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 122, 4129-4139 (2013).
18. Davila, M.L., Kloss, C.C., Gunset, G. & Sadelain, M. CD19 CAR-targeted T cells induce long-term remission and B cell aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia. PLoS One 8, e61338 (2013).
19. Ghosh, A. et al. PLZF confers effector functions to donor T cells that preserve graft-versus-tumor effects while attenuating GVHD. Cancer Res. 73, 4687-4696 (2013).
20. Ghosh, A. et al. Adoptively transferred TRAIL+ T cells suppress GVHD and augment antitumor activity. J. Clin. Invest. 123, 2654-2662 (2013).
21. Bar, M. et al. Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose. Biol. Blood Marrow Transplant. 19, 949-957 (2013).
22. Srinivasan, M. et al. Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood 119, 1570-1580 (2012).
23. Jacoby, E. et al. Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD. Blood 127, 1361-1370 (2016).
24. Kochenderfer, J.N., Yu, Z., Frasheri, D., Restifo, N.P. & Rosenberg, S.A. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood 116, 3875-3886 (2010).
25. Jenq, R.R. et al. Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J. Exp. Med. 209, 903-911 (2012).
26. Zhao, Z. et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell 28, 415-428 (2015).
27. Long, A.H. et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat. Med. 21, 581-590 (2015).
28. Hasan, M., Polic, B., Bralic, M., Jonjic, S. & Rajewsky, K. Incomplete block of B cell development and immunoglobulin production in mice carrying the μ MT mutation on the BALB/c background. Eur. J. Immunol. 32, 3463-3471 (2002).
29. Rickert, R.C., Roes, J. & Rajewsky, K. B lymphocyte-specific, Cre-mediated mutagenesis in mice. Nucleic Acids Res. 25, 1317-1318 (1997).
30. Wherry, E.J. T cell exhaustion. Nat. Immunol. 12, 492-499 (2011).
31. Teague, R.M. et al. Peripheral CD8+ T cell tolerance to self-proteins is regulated proximally at the T cell receptor. Immunity 28, 662-674 (2008).
32. Schietinger, A., Delrow, J.J., Basom, R.S., Blattman, J.N. & Greenberg, P.D. Rescued tolerant CD8 T cells are preprogrammed to reestablish the tolerant state. Science 335, 723-727 (2012).
33. Paley, M.A. et al. Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science 338, 1220-1225 (2012).
34. Gattinoni, L. et al. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat. Med. 15, 808-813 (2009).
35. Cruz, C.R. et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood 122, 2965-2973 (2013).
36. Small, T.N., Robinson, W.H. & Miklos, D.B. B cells and transplantation: an educational resource. Biol. Blood Marrow Transplant. 15 (Suppl.), 104-113 (2009).
37. Sayegh, M.H. et al. Allograft rejection in a new allospecific CD4+ TCR transgenic mouse. Am. J. Transplant. 3, 381-389 (2003).
38. Schmaltz, C. et al. T cells require TRAIL for optimal graft-versus-tumor activity. Nat. Med. 8, 1433-1437 (2002).
39. Rivière, I., Brose, K. & Mulligan, R.C. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc. Natl. Acad. Sci. USA 92, 6733-6737 (1995).
40. Lee, J., Sadelain, M. & Brentjens, R. Retroviral transduction of murine primary T lymphocytes. Methods Mol. Biol. 506, 83-96 (2009).
41. Zheng, Z., Chinnasamy, N. & Morgan, R.A. Protein L: a novel reagent for the detection of chimeric antigen receptor (CAR) expression by flow cytometry. J. Transl. Med. 10, 29 (2012).
42. Irizarry, R.A. et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4, 249-264 (2003).
43. Smyth, G.K. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3, Article 3 (2004).